Chair and Department of Infectious Diseases, Hepatology and Acquired Immunodeficiencies, Karol Marcinkowski University of Medical Sciences, Poznań, Poland.
Chair of Clinical Immunology, Karol Marcinkowski University of Medical Sciences, Poznań, Poland.
Sci Rep. 2020 Jun 25;10(1):10388. doi: 10.1038/s41598-020-67296-9.
Chronic viral hepatitis C (CHC) and its complications have a negative effect on patient's quality of life. We evaluated the impact of a successful interferon-free treatment on the quality of life of patients with obesity and metabolic disorders in the context of immunological disturbances. Twenty overweight or obese (BMI > 25) patients with CHC were tested before the therapy and after a successful treatment regimen. After the therapy, patient's emotional well-being improved (p = 0.02), while physical well-being remained unchanged. There was a decrease of patient's liver fibrosis and an increase of steatosis along with body mass. Among HCV-infected individuals, the expression of toll-like receptor 3 (TLR3) on lymphocytes was higher than in the control group (p = 0.03), but it decreased (p = 0.001) after the treatment. There was also a decrease of the intensity of immunofluorescence of FoxP3+ after the treatment (p = 0.04). Our study showed an improvement in mental aspects of patient's quality of life after the treatment. Unfortunately, probably due to rapid immunological changes, patient's BMI, serum cholesterol levels and hepatic steatosis have a tendency to increase and may lead to cardiovascular and other complications, like hepatocellular carcinoma.
慢性丙型病毒性肝炎（CHC）及其并发症对患者的生活质量有负面影响。我们评估了在免疫紊乱的情况下，无干扰素治疗成功对肥胖和代谢紊乱患者生活质量的影响。20 名超重或肥胖（BMI>25）的 CHC 患者在治疗前和成功治疗方案后接受了检测。治疗后，患者的情绪健康状况有所改善（p=0.02），而身体状况保持不变。患者的肝纤维化减少，脂肪变性随着体重增加而增加。在 HCV 感染个体中，淋巴细胞上的 toll 样受体 3（TLR3）的表达高于对照组（p=0.03），但治疗后其表达降低（p=0.001）。FoxP3+的免疫荧光强度也在治疗后降低（p=0.04）。我们的研究表明，治疗后患者生活质量的心理方面有所改善。不幸的是，可能由于快速的免疫变化，患者的 BMI、血清胆固醇水平和肝脂肪变性有增加的趋势，可能导致心血管和其他并发症，如肝细胞癌。
Zotero 插件
